SLDB Solid Corp: Business Value

Solid Corp (SLDB) - corporate logo

Solid Biosciences Inc. (SLDB) revenue is based on the market launch of gene therapies to combat rare muscle pathologies. Financial stability relies on future payments from insurance organizations and government funds for patient treatment. This price chart shows an Enterprise Value of 305.57, while business success depends on the safety of clinical trials, which temporarily precludes price wars with competitors.

SLDB Solid Corp: Enterprise Value in the range 11/23/2025 - 10/28/2026

Solid Biosciences Inc. (SLDB) - metric breakdowns and financial figures

- price and consensus price forecast:
Price Chart Solid Biosciences Inc|SLDB - Analyst Consensus Forecast
- market capitalization data:
Market Capitalization Solid Biosciences|SLDB - Enterprise Value
- book capitalization data:
Net Assets per Single Share Solid Biosciences|SLDB - Book Capitalization|Capitalization to Book Value Ratio solidbio.com|SLDB - Aggregate Company Assets
- debt and liquidity data:
Debt to Equity Ratio Solid Biosciences Inc.|SLDB - Long-Term Debt to Capital|Short-Term Debt to Capital solidbio.com|SLDB - Company Debts|Debts to Net Assets Solid Biosciences
General company analysis:Solid Biosciences Inc (SLDB)
Original product of Solid Biosciences Inc.

Solid Biosciences Inc. (SLDB) management's focus on developing the SGT-003 gene therapy requires strict liquidity control to fund clinical phases. By analyzing the Enterprise Value (EV), an investor can determine the total business value, where market capitalization is adjusted for net debt, allowing for an assessment of the actual acquisition cost considering the company's existing cash reserves.

Direct competitors

Total Company Value Tempus AI TEM|Qiagen Group (QGEN) - Enterprise Value|IONS - Business Value|Repligen Corporation (RGEN) - Enterprise Value|aviditybiosciences.com (RNA) - Total Company Value|Enterprise Value CRISPR Therapeutics (CRSP)|Business Value WGS|Total Company Value Ultragenyx Pharma RARE|Business Value Beam Tx (BEAM)|Enterprise Value SRPT (Sarepta Therapeutics, Inc.)|twistbioscience.com - Enterprise Value|Total Company Value TXG (10x Genomics)|NTLA: Company Buyout Price|Total Company Value STOK|BLFS (BioLife) - Total Enterprise Value|Total Company Value Wave Life Sciences|Total Company Value mazetx.com|SION (Sionna Therapeutics) - Enterprise Value|Company Buyout Price Prime Medicine Inc (PRME)|TSHA - Enterprise Value|QURE - Business Value|Real Price to Acquire Entire Company MeiraGTx Holdings plc (MGTX)|RGNX - Value Adjusted for Debt and Cash|Ocugen (OCGN) - Enterprise Value|Pacific Biosciences of California, Inc. (PACB) - Total Company Value|BNTC: Enterprise Value|Company Buyout Price DSGN|Rocket Pharmaceuticals - Total Company Value|Total Enterprise Value FDMT (4dmoleculartherapeutics.com)|Total Company Value LXEO|Company Buyout Price Korro Bio Inc. KRRO|EDIT: Enterprise Value|SLN - Real Price to Acquire Entire Company|proqr.com - Enterprise Value|Codexis (CDXS) - Company Buyout Price|Enterprise Value SGMO (Sangamo Therapeutics, Inc.)|Total Enterprise Value NAUT|Total Company Value Metagenomi, Inc MGX|Business Value precisionbiosciences.com (DTIL)|Generation Bio - Enterprise Value|Real Price to Acquire Entire Company boundlessbio.com BOLD|XCUR (Exicure Corp) - Enterprise Value|IMNN: Total Enterprise Value|phiopharma.com - Total Company Value|Company Buyout Price Mustang Bio|RNAZ - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash Bionano|APDN (Applied DNA Sciences, Inc.) - Enterprise Value|Company Buyout Price BLUE (bluebird bio Inc.)|IPA - Total Company Value|Business Value Omega Therapeutics Corp OMGA|OMIC: Enterprise Value|regulusrx.com (RGLS) - Real Price to Acquire Entire Company|Syros Pharmaceuticals, Inc. - Real Price to Acquire Entire Company|TBIO (Telesis Bio Inc.) - Company Buyout Price|TCON: Total Company Value|Company Buyout Price UBX